Fintech lender Affirm has started quietly offering "buy now, pay later" (BNPL) loans for elective medical procedures, in a major push beyond its core e-commerce market, the company told Reuters.

More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) ...